The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy; including Pegylated L-Asparaginase and have a central line (a catheter inserted for administration of medications and blood sampling).
Complete study information: https://clinicaltrials.gov/ct2/show/NCT02369653
Patients:
Bristol Myers - Squibb
Director, Divisional Research, Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program